File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Conference Paper: Prediction of posthepatectomy recurrence of hepatocellular carcinoma by circulating cancer stem cells: A prospective study
  • Basic View
  • Metadata View
  • XML View
TitlePrediction of posthepatectomy recurrence of hepatocellular carcinoma by circulating cancer stem cells: A prospective study
 
AuthorsFan, ST2
Yang, ZF2 1
Ho, DWY2
Ng, MNP2
Yu, WC2
Wong, J2
 
Issue Date2011
 
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.annalsofsurgery.com
 
CitationAnnals Of Surgery, 2011, v. 254 n. 4, p. 569-576 [How to Cite?]
DOI: http://dx.doi.org/10.1097/SLA.0b013e3182300a1d
 
AbstractOBJECTIVE: To investigate whether circulating cancer stem cells (CSCs) of hepatocellular carcinoma (HCC) can predict its recurrence after hepatectomy. BACKGROUND: HCC recurrence frequently occurs within the first year after hepatectomy, probably due to circulating tumor cells that have been shed from the primary tumor before hepatectomy. Because CSCs are more likely to initiate tumor growth than mature cancer cells, a high level of circulating CSCs may be a hint for HCC recurrence. METHODS: Multicolor flow cytometry was used to detect the number of circulating CSCs (CD45 -CD90 +CD44 +) in the peripheral circulation of 82 HCC patients 1 day before hepatectomy. The patients were monitored by CT or MRI for recurrence every 3 months. RESULTS: Forty-one (50%) patients had recurrence after a median follow-up period of 13.2 months (range, 1.3-57.1 months). Patients with recurrence had a higher median level of circulating CSCs than patients without recurrence (0.02% vs. 0.01%; P < 0.0001). Circulating CSCs > 0.01% predicted intrahepatic recurrence (relative risk 3.54; 95% CI, 1.41-8.88; P = 0.007) and extrahepatic recurrence (relative risk 10.15; 95% CI, 3-34.4; P = 0.0002). Patients with >0.01% circulating CSCs had a lower 2-year recurrence-free survival rate (22.7% vs. 64.2%; P < 0.0001) and overall survival rate (58.5% vs. 94.1%; P = 0.0005) than patients with ≤0.01% circulating CSCs. On multivariable analysis, circulating CSCs > 0.01%, tumor stage and tumor size were independent factors predicting recurrence-free survival. CONCLUSIONS: Circulating CSCs predicted posthepatectomy HCC recurrence with high accuracy. They may be the target of eradication in the prevention of posthepatectomy HCC metastasis and recurrence. Copyright © 2011 by Lippincott Williams & Wilkins.
 
DescriptionPapers of the 131st ASA annual meeting
 
ISSN0003-4932
2013 Impact Factor: 7.188
 
DOIhttp://dx.doi.org/10.1097/SLA.0b013e3182300a1d
 
ISI Accession Number IDWOS:000295162400004
Funding AgencyGrant Number
University of Hong Kong, Hong Kong, China
Funding Information:

Supported by Mrs. Li Ka Shing Fund, The University of Hong Kong, Hong Kong, China.

 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorFan, ST
 
dc.contributor.authorYang, ZF
 
dc.contributor.authorHo, DWY
 
dc.contributor.authorNg, MNP
 
dc.contributor.authorYu, WC
 
dc.contributor.authorWong, J
 
dc.date.accessioned2011-10-28T02:50:56Z
 
dc.date.available2011-10-28T02:50:56Z
 
dc.date.issued2011
 
dc.description.abstractOBJECTIVE: To investigate whether circulating cancer stem cells (CSCs) of hepatocellular carcinoma (HCC) can predict its recurrence after hepatectomy. BACKGROUND: HCC recurrence frequently occurs within the first year after hepatectomy, probably due to circulating tumor cells that have been shed from the primary tumor before hepatectomy. Because CSCs are more likely to initiate tumor growth than mature cancer cells, a high level of circulating CSCs may be a hint for HCC recurrence. METHODS: Multicolor flow cytometry was used to detect the number of circulating CSCs (CD45 -CD90 +CD44 +) in the peripheral circulation of 82 HCC patients 1 day before hepatectomy. The patients were monitored by CT or MRI for recurrence every 3 months. RESULTS: Forty-one (50%) patients had recurrence after a median follow-up period of 13.2 months (range, 1.3-57.1 months). Patients with recurrence had a higher median level of circulating CSCs than patients without recurrence (0.02% vs. 0.01%; P < 0.0001). Circulating CSCs > 0.01% predicted intrahepatic recurrence (relative risk 3.54; 95% CI, 1.41-8.88; P = 0.007) and extrahepatic recurrence (relative risk 10.15; 95% CI, 3-34.4; P = 0.0002). Patients with >0.01% circulating CSCs had a lower 2-year recurrence-free survival rate (22.7% vs. 64.2%; P < 0.0001) and overall survival rate (58.5% vs. 94.1%; P = 0.0005) than patients with ≤0.01% circulating CSCs. On multivariable analysis, circulating CSCs > 0.01%, tumor stage and tumor size were independent factors predicting recurrence-free survival. CONCLUSIONS: Circulating CSCs predicted posthepatectomy HCC recurrence with high accuracy. They may be the target of eradication in the prevention of posthepatectomy HCC metastasis and recurrence. Copyright © 2011 by Lippincott Williams & Wilkins.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.descriptionPapers of the 131st ASA annual meeting
 
dc.identifier.citationAnnals Of Surgery, 2011, v. 254 n. 4, p. 569-576 [How to Cite?]
DOI: http://dx.doi.org/10.1097/SLA.0b013e3182300a1d
 
dc.identifier.doihttp://dx.doi.org/10.1097/SLA.0b013e3182300a1d
 
dc.identifier.epage576
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.f100014257962
 
dc.identifier.hkuros196688
 
dc.identifier.isiWOS:000295162400004
Funding AgencyGrant Number
University of Hong Kong, Hong Kong, China
Funding Information:

Supported by Mrs. Li Ka Shing Fund, The University of Hong Kong, Hong Kong, China.

 
dc.identifier.issn0003-4932
2013 Impact Factor: 7.188
 
dc.identifier.issue4
 
dc.identifier.openurl
 
dc.identifier.pmid21892074
 
dc.identifier.scopuseid_2-s2.0-80053284820
 
dc.identifier.spage569
 
dc.identifier.urihttp://hdl.handle.net/10722/142543
 
dc.identifier.volume254
 
dc.languageeng
 
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.annalsofsurgery.com
 
dc.publisher.placeUnited States
 
dc.relation.ispartofAnnals of Surgery
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshCarcinoma, Hepatocellular - blood - surgery
 
dc.subject.meshHepatectomy
 
dc.subject.meshLiver Neoplasms - blood - surgery
 
dc.subject.meshNeoplasm Recurrence, Local - blood - epidemiology
 
dc.subject.meshNeoplastic Stem Cells
 
dc.titlePrediction of posthepatectomy recurrence of hepatocellular carcinoma by circulating cancer stem cells: A prospective study
 
dc.typeConference_Paper
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Fan, ST</contributor.author>
<contributor.author>Yang, ZF</contributor.author>
<contributor.author>Ho, DWY</contributor.author>
<contributor.author>Ng, MNP</contributor.author>
<contributor.author>Yu, WC</contributor.author>
<contributor.author>Wong, J</contributor.author>
<date.accessioned>2011-10-28T02:50:56Z</date.accessioned>
<date.available>2011-10-28T02:50:56Z</date.available>
<date.issued>2011</date.issued>
<identifier.citation>Annals Of Surgery, 2011, v. 254 n. 4, p. 569-576</identifier.citation>
<identifier.issn>0003-4932</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/142543</identifier.uri>
<description>Papers of the 131st ASA annual meeting</description>
<description.abstract>OBJECTIVE: To investigate whether circulating cancer stem cells (CSCs) of hepatocellular carcinoma (HCC) can predict its recurrence after hepatectomy. BACKGROUND: HCC recurrence frequently occurs within the first year after hepatectomy, probably due to circulating tumor cells that have been shed from the primary tumor before hepatectomy. Because CSCs are more likely to initiate tumor growth than mature cancer cells, a high level of circulating CSCs may be a hint for HCC recurrence. METHODS: Multicolor flow cytometry was used to detect the number of circulating CSCs (CD45 -CD90 +CD44 +) in the peripheral circulation of 82 HCC patients 1 day before hepatectomy. The patients were monitored by CT or MRI for recurrence every 3 months. RESULTS: Forty-one (50%) patients had recurrence after a median follow-up period of 13.2 months (range, 1.3-57.1 months). Patients with recurrence had a higher median level of circulating CSCs than patients without recurrence (0.02% vs. 0.01%; P &lt; 0.0001). Circulating CSCs &gt; 0.01% predicted intrahepatic recurrence (relative risk 3.54; 95% CI, 1.41-8.88; P = 0.007) and extrahepatic recurrence (relative risk 10.15; 95% CI, 3-34.4; P = 0.0002). Patients with &gt;0.01% circulating CSCs had a lower 2-year recurrence-free survival rate (22.7% vs. 64.2%; P &lt; 0.0001) and overall survival rate (58.5% vs. 94.1%; P = 0.0005) than patients with &#8804;0.01% circulating CSCs. On multivariable analysis, circulating CSCs &gt; 0.01%, tumor stage and tumor size were independent factors predicting recurrence-free survival. CONCLUSIONS: Circulating CSCs predicted posthepatectomy HCC recurrence with high accuracy. They may be the target of eradication in the prevention of posthepatectomy HCC metastasis and recurrence. Copyright &#169; 2011 by Lippincott Williams &amp; Wilkins.</description.abstract>
<language>eng</language>
<publisher>Lippincott Williams &amp; Wilkins. The Journal&apos;s web site is located at http://www.annalsofsurgery.com</publisher>
<relation.ispartof>Annals of Surgery</relation.ispartof>
<subject.mesh>Carcinoma, Hepatocellular - blood - surgery</subject.mesh>
<subject.mesh>Hepatectomy</subject.mesh>
<subject.mesh>Liver Neoplasms - blood - surgery</subject.mesh>
<subject.mesh>Neoplasm Recurrence, Local - blood - epidemiology</subject.mesh>
<subject.mesh>Neoplastic Stem Cells</subject.mesh>
<title>Prediction of posthepatectomy recurrence of hepatocellular carcinoma by circulating cancer stem cells: A prospective study</title>
<type>Conference_Paper</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0003-4932&amp;volume=254&amp;issue=4&amp;spage=569&amp;epage=576&amp;date=2011&amp;atitle=Prediction+of+posthepatectomy+recurrence+of+hepatocellular+carcinoma+by+circulating+cancer+stem+cells:+a+prospective+study</identifier.openurl>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1097/SLA.0b013e3182300a1d</identifier.doi>
<identifier.pmid>21892074</identifier.pmid>
<identifier.scopus>eid_2-s2.0-80053284820</identifier.scopus>
<identifier.hkuros>196688</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-80053284820&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>254</identifier.volume>
<identifier.issue>4</identifier.issue>
<identifier.spage>569</identifier.spage>
<identifier.epage>576</identifier.epage>
<identifier.isi>WOS:000295162400004</identifier.isi>
<publisher.place>United States</publisher.place>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
<identifier.f1000>14257962</identifier.f1000>
</item>
Author Affiliations
  1. AstraZeneca
  2. The University of Hong Kong